MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment-Reference-Cited by-同舟云学术

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

Published:2018-05-16 Issue:3 Volume:182 Page:360-372
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Crassini Kyle¹^ORCID,Shen Yandong¹²,Stevenson William S.¹,Christopherson Richard²,Ward Chris¹,Mulligan Stephen P.¹³²,Best O. Giles¹³²^ORCID

Affiliation:

1. Northern Blood Research Centre; Kolling Institute of Medical Research; Royal North Shore Hospital; St Leonards Sydney Australia

2. School of Molecular Biosciences; University of Sydney; Sydney Australia

3. CLL Australian Research Consortium (CLLARC); Kolling Institute of Medical Research, St Leonards; Sydney Australia

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15282/fullpdf

Reference45 articles.

1. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance;Balakrishnan;Blood,2009

2. Tumour cell survival signalling by the ERK1/2 pathway;Balmanno;Cell Death and Differentiation,2009

3. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL;Best;Leukemia,2008

4. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199;Bojarczuk;Blood,2016

5. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment;Burger;Blood,2006

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia;Frontiers in Oncology;2024-02-26

2. Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

3. Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia;The Journal of Immunology;2022-09-15

4. In Vitro and In Vivo Models of CLL–T Cell Interactions: Implications for Drug Testing;Cancers;2022-06-23

5. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma;Leukemia;2022-06-20